Myriad Genetics director granted 59,701 RSUs
Myriad Genetics director Daniel Skovronsky received an equity award of 59,701 shares of common stock in the form of restricted stock units.
Rhea-AI Filing Summary
Myriad Genetics director Daniel Skovronsky received an equity award of 59,701 shares of common stock in the form of restricted stock units. The grant was made at no cash cost to him and represents compensation rather than an open-market purchase.
Each restricted stock unit converts into one share of Myriad Genetics common stock and will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this award, Skovronsky holds a total of 195,507 shares of common stock directly.
Insider Trade Summary
Grant/Award: 59,701 shares
Grant/Award
1 txn
Insider
Skovronsky Daniel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 59,701 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 195,507 shares (Direct)
Footnotes (1)
- F1. Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
Key Figures
RSU grant size: 59,701 shares
Price per share for grant: $0.0000 per share
Shares held after transaction: 195,507 shares
+2 more
5 metrics
RSU grant size
59,701 shares
Restricted stock units of common stock granted to director
Price per share for grant
$0.0000 per share
Equity award granted at no cash cost to recipient
Shares held after transaction
195,507 shares
Total common stock directly owned by Daniel Skovronsky after award
Vesting condition – anniversary
First anniversary of grant date
One of the vesting triggers for the restricted stock units
Vesting condition – annual meeting
Next annual meeting of stockholders
Alternative vesting trigger for the restricted stock units
Key Terms
restricted stock units, 2026 Employee, Director and Consultant Equity Incentive Plan, annual meeting of stockholders
3 terms
restricted stock units financial
"Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2026 Employee, Director and Consultant Equity Incentive Plan financial
"granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended"
annual meeting of stockholders regulatory
"vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Myriad Genetics (MYGN) report for Daniel Skovronsky?
Myriad Genetics reported that director Daniel Skovronsky received 59,701 restricted stock units as an equity award. These units represent compensation and not an open-market share purchase, and each unit corresponds to one share of the company’s common stock upon vesting.
What are the vesting terms of Daniel Skovronsky’s 59,701 restricted stock units at Myriad Genetics?
The 59,701 restricted stock units vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Each vested unit entitles Daniel Skovronsky to receive one share of Myriad Genetics common stock, subject to the plan’s conditions.
Under which plan were Daniel Skovronsky’s restricted stock units in Myriad Genetics granted?
The restricted stock units were granted under Myriad Genetics’ 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. This plan provides equity-based awards to directors, employees, and consultants, aligning their compensation with the company’s common stock performance over time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
